MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE
Clinical trials for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE explained in plain language.
Never miss a new study
Get alerted when new MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE trials appear
Sign up with your email to follow new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Turmeric and black pepper extract shows promise in slowing early cancers
Disease control CompletedThis study tested a daily supplement of curcumin (from turmeric) and piperine (from black pepper) in 30 people with early-stage prostate cancer or pre-cancerous blood conditions (MGUS or low-risk smoldering multiple myeloma). The goal was to see if the supplement could lower canc…
Matched conditions: MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
Blood marker may reveal bone damage in myeloma
Knowledge-focused CompletedThis study looked at whether a substance in the blood called M-CSF can help doctors find bone damage in people with multiple myeloma. Researchers compared M-CSF levels in 111 people: those with multiple myeloma, those with a pre-cancer condition called MGUS, and healthy volunteer…
Matched conditions: MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 16, 2026 22:33 UTC
-
Can new scans predict myeloma before it strikes?
Knowledge-focused CompletedThis study looked at whether newer imaging techniques can better detect when a person with early blood conditions (MGUS or smoldering myeloma) is developing active multiple myeloma. Thirty-one adults with these conditions received three types of scans: a standard PET/CT, an exper…
Matched conditions: MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:56 UTC